Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.62 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.62 |
| ▸ | CTSD | P07339 | 2/20 | 0.60 |
| ▸ | CTSE | P14091 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044164 | 0.94 | BACE1 (0.61) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6044190 | 0.87 | BACE1 (0.61) | BACE1BACE2CTSD | |
| SCHEMBL6044289 | 0.87 | BACE1 (0.66) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6044429 | 0.85 | BACE1 (0.61) | BACE1BACE2CTSD | |
| SCHEMBL8364974 | 0.85 | BACE1 (0.78) | BACE1BACE2CTSDCTSE | |
| SCHEMBL6044181 | 0.85 | BACE1 (0.62) | BACE1BACE2CTSD | |
| SCHEMBL6043906 | 0.83 | BACE1 (0.64) | BACE1BACE2CTSDCTSE | |
| SCHEMBL5367552 | 0.83 | BACE1 (0.69) | BACE1BACE2CTSD | |
| SCHEMBL5579146 | 0.83 | BACE1 (0.69) | BACE1BACE2CTSD | |
| SCHEMBL5633480 | 0.83 | BACE1 (0.69) | BACE1BACE2CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | BACE1, APP, BACE2 | BACE1 1/4885BACE2 3/4885CTSD 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.